Clinical Trial Search

Primary: Number and Seriousness of Both Local and Systemic Adverse Reactions — 2; 1; 0; 1 adverse reactions number

Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of…

Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38

Primary: D. Farinae Specific IgG4 Change From Baseline to End of Treatment — 0.473; -0.01 mg antibody/ml

Primary: The Primary Outcome Measure for This Study is the Number of Sputum Myeloid Dendritic Cells — 32800; 89100 number of cells/g of sputum

Primary: Average Daily Asthma Medication Score During a 2-months Evaluation Period in Autumn 2008 — 4.4; 4.7 Scores on a scale — p=0.85

Primary: Area Under the Curve (AUC) of Percent Change in Forced Expiratory Volume in 1 Second (FEV1) Over a 1-hour Cat Allergen Exposure From Pre-challenge at Week 16 — 15.03…

Primary: Bronchial Threshold to Allergen Challenge From Baseline to 12-18 Months of Treatment — 75.0; 69.5; 141.4; 74.8 cumulative breath units

Primary: Effect of FP-025 Versus Placebo on the Allergen (HDM)-Induced Late Asthmatic Response (LAR) in Subjects With Clinically Stable, Mild Allergic Asthma and Blood…

Primary: Number of Reported Adverse Events (AEs) — 9; 1; 1; 2 Events

Primary: Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With…

Primary: Annualized Rate of Clinically Relevant Asthma Exacerbations — 0.18; 0.21 Exacerbations per year per participant — p=0.5412

Primary: Average Daily Total Combined Rhinitis Symptom and Medication Score (TCRS) During the Primary Efficacy Assessment Period — 3.4; 4.4 score on a scale — p=<0.0001

Primary: Change From Baseline to the End-of-treatment Period in the Area Under the Curve of the Rhinitis Total Symptom Score Recorded During 4 Hours (0-4h) of the Allergen…

Primary: Time to Early Asthmatic Response (EAR) Upon Controlled Cat Allergen Challenge in an Environmental Exposure Unit (EEU) on Day 8 — 51; NA Minutes — p== 0.0083

Primary: Change in Mean Total Nasal Symptom Score (TNSS) From Baseline to 12 Months Between Cockroach SCIT and Placebo — -1.02; -0.79 score on a scale — p=0.63

Primary: Change in TSLP Gene Expression — 0.000197; 0.000035 Fold Change

Primary: Overall Change From Baseline in TNSS at Visits 3, 4 and 5 — 3.9; 4.1; 5.2 TNSS score (0-12) — p=0.0085

Primary: Variation of the Concentration of Phleum Pratense Extract Needed to Produce a Positive Nasal Provocation Test From Baseline (V0) to Final Visit (FV). — 0.493; 0.275…

Primary: The Change From Baseline in Rhinoconjunctivitis Symptoms Score at 11 - 12 Months Between the Actively Treated Patients and the Placebo Treated. — -1.77; -1.83 units on a…

Primary: Number of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) — 223 subjects

Primary: Maximum Symptom Days/14 Days — 2.7 days

Primary: Average Adjusted Symptom Score (AAdSS) During the Year 1 Primary Period — 3.18; 3.09; 3.87 Units on a scale (range: 0 to 12) — p=0.0066

Primary: Safety and Tolerability Evaluated on Treatment Emergent Adverse Events — 4; 6; 9; 4 participants

Primary: Characterize Contribution of Histamine in Children With Asthma — 11253.24; 6464.20; 3539.67 flux units on a continuous scale

Primary: Number of Participants With Change in Sputum Markers by End of Study — 0; 0 Participants

Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage

Primary: Change From Baseline in the Expression of FcεRI Receptors of Blood Basophils — -84.4; 27.7 Percent change in MFI

Primary: Daily Symptom Load — 1.25; 1.10; 1.32; 0.97 units on a scale

Primary: Late Asthmatic Response (LAR): Minimum FEV1 Between 4-10 Hours After Allergen Challenge on Day 13 of Each Treatment Period — -0.903; -0.663; -0.638; -0.446 Liters